Premium
Caspase Inhibitors as a Supplement in Immune Activation Therapies to Achieve Eradication of HIV in Its Latent Reservoirs
Author(s) -
SCHELLER CARSTEN,
SOPPER SIEGHART,
KOUTSILIERI ELENI,
LUDWIG STEPHAN,
MEULEN VOLKER,
JASSOY CHRISTIAN
Publication year - 2003
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1196/annals.1299.036
Subject(s) - proinflammatory cytokine , apoptosis , caspase 8 , immune system , human immunodeficiency virus (hiv) , caspase , tumor necrosis factor alpha , immunology , medicine , biology , pharmacology , virology , programmed cell death , inflammation , biochemistry
A bstract : Synthetic caspase inhibitors are known to block death receptor‐induced apoptosis. We have reported previously that in addition to apoptosis inhibition, caspase inhibitors induce a switch from proapoptotic to proinflammatory signaling in T cells. This switch sensitizes TNF‐R1 to trigger TNF‐α‐induced reactivation of HIV in latently infected T cells. Here we ponder the prospects of caspase inhibitors as a supplement in immune activation therapies (IAT) to achieve eradication of HIV from the latent virus reservoirs in HIV‐infected patients.